The goal of current study is to examine the relationship between HE4 and clinicopathological variables, and to assess the value of serum HE4 for the screening and/or diagnosis of pancreatic adenocarcinoma either alone or in combination with additional serum markers. The gene discussed is WFDC2; the disease is pancreatic adenocarcinoma.